TESARO Company Profile (NASDAQ:TSRO)

About TESARO (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:TSRO
CUSIP: 88156910
Web: www.tesarobio.com

Capitalization:

Market Cap: $6.25844 billion
Outstanding Shares: 54,180,000

Average Prices:

50 Day Moving Avg: $121.22
200 Day Moving Avg: $133.02
52 Week Range: $106.64 - $192.94

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -22.78
P/E Growth: -0.53

Sales & Book Value:

Annual Revenue: $41.25 million
Price / Sales: 152.89
Book Value: $7.38 per share
Price / Book: 15.77

Profitability:

EBITDA: ($485,860,000.00)
Net Margins: -1,301.19%
Return on Equity: -104.00%
Return on Assets: -71.79%

Debt:

Debt-to-Equity Ratio: 0.34%
Current Ratio: 5.69%
Quick Ratio: 5.41%

Misc:

Average Volume: 845,998 shs.
Beta: 1.59
Short Ratio: 7.96

Frequently Asked Questions for TESARO (NASDAQ:TSRO)

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO, Inc. (NASDAQ:TSRO) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.52) by $0.30. The business had revenue of $29.50 million for the quarter, compared to analysts' expectations of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm's revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.28) EPS. View TESARO's Earnings History.

When will TESARO make its next earnings announcement?

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for TESARO.

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

22 brokers have issued 1 year target prices for TESARO's stock. Their predictions range from $120.00 to $236.00. On average, they expect TESARO's stock price to reach $169.82 in the next year. View Analyst Ratings for TESARO.

What are analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

1. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (10/17/2017)
2. Cann analysts commented, "These results are an analysis of the phase I/II TOPACIO study of niraparib plus pembrolizumab in combination with pembrolizumab (Keytruda) in patients with triple negative breast cancer (TNBC) or ovarian cancer. Safety and efficacy were presented from both the dose-finding portion as well as the dose-expansion portion of the study. We believe these data released today support a path forward for Tesaro in the TNBC setting with Zejula. TNBC is a particularly challenging setting. There are many studies from numerous drug sponsors underway and TNBC, but there is no established reference standard for this disease." (9/8/2017)
3. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
4. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Are investors shorting TESARO?

TESARO saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 6,767,191 shares, a decrease of 28.5% from the September 15th total of 9,459,637 shares. Based on an average daily trading volume, of 570,698 shares, the days-to-cover ratio is presently 11.9 days. Currently, 17.9% of the shares of the stock are sold short.

Who are some of TESARO's key competitors?

Some companies that are related to TESARO include Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), BIOVERATIV INC (BIVV), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), AveXis (AVXS), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), Loxo Oncology (LOXO) and Array BioPharma (ARRY).

Who are TESARO's key executives?

TESARO's management team includes the folowing people:

David M. Mott, Independent Chairman of the Board
Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
Leon O. Moulder Jr., Chief Executive Officer, Director
Timothy R. Pearson, Chief Financial Officer, Executive Vice President
Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
Grant C. Bogle, Senior Vice President, Chief Commercial Officer
Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
Lawrence M. Alleva, Independent Director
James O. Armitage M.D., Independent Director

Who owns TESARO stock?

TESARO's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Exane Derivatives (0.00%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Institutional Ownership Trends for TESARO.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky and Enterprise Associates 13 L New. View Insider Buying and Selling for TESARO.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TESARO stock can currently be purchased for approximately $116.40.

MarketBeat Community Rating for TESARO (NASDAQ TSRO)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		417 (Vote Outperform)
Underperform Votes:		236 (Vote Underperform)
Total Votes:		653

MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for TESARO (NASDAQ:TSRO) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	8 Hold Ratings, 14 Buy Ratings
Consensus Rating:	Buy (Score: 2.64)
Consensus Price Target:	$169.82 (45.89% upside)

Consensus Price Target History for TESARO (NASDAQ:TSRO)

Analysts' Ratings History for TESARO (NASDAQ:TSRO)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/12/2017	HC Wainwright	Initiated Coverage	Buy -> Buy	$158.00	N/A
10/2/2017	Robert W. Baird	Reiterated Rating	Neutral	$125.00	Low
9/14/2017	Royal Bank Of Canada	Initiated Coverage	Sector Perform	$120.00	Medium
9/11/2017	Wedbush	Reiterated Rating	Outperform	$160.00	Low
9/10/2017	Oppenheimer Holdings, Inc.	Reiterated Rating	Buy	$199.00	Low
9/11/2017	Citigroup Inc.	Reiterated Rating	Buy	$216.00	Low
9/8/2017	Cann	Reiterated Rating	Buy	$199.00	Low
8/20/2017	SunTrust Banks, Inc.	Reiterated Rating	Buy	$235.00	High
8/20/2017	Wells Fargo & Company	Reiterated Rating	Outperform		High
8/17/2017	Jefferies Group LLC	Set Price Target	Hold	$124.00	High
8/18/2017	Credit Suisse Group	Set Price Target	Buy	$198.00 -> $190.00	High
8/16/2017	Evercore ISI	Initiated Coverage	In -> In-Line	$121.00	High
8/10/2017	Morgan Stanley	Reiterated Rating	Overweight	$183.00	High
7/14/2017	Janney Montgomery Scott	Reiterated Rating	Neutral		Low
7/7/2017	Gabelli	Initiated Coverage	Buy	$175.00	High
6/20/2017	Raymond James Financial, Inc.	Reiterated Rating	Market Perform		Medium
6/20/2017	Leerink Swann	Lower Price Target	Market Perform	$164.00 -> $143.00	High
6/20/2017	Bank of America Corporation	Reiterated Rating	Buy	$154.00	High
6/19/2017	Cowen and Company	Lower Price Target	Market Perform	$145.00 -> $124.00	High
6/5/2017	FBR & Co	Lower Price Target	Mkt Perform -> Mkt Perform	$200.00 -> $195.00	High
4/12/2017	Piper Jaffray Companies	Initiated Coverage	Overweight -> Overweight	$180.00	Low
3/24/2017	Argus	Initiated Coverage	Buy	$210.00	High
11/7/2016	Lake Street Capital	Reiterated Rating	Buy	$114.00 -> $150.00	N/A
8/5/2016	Mizuho	Lower Price Target	Buy	$100.00 -> $94.00	N/A

(Data available from 10/21/2015 forward)

Earnings History for TESARO (NASDAQ:TSRO)

Earnings by Quarter for TESARO (NASDAQ:TSRO)

Earnings History by Quarter for TESARO (NASDAQ TSRO)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2017		($1.16)					N/A
8/8/2017	Q2 2017	($2.52)	($2.82)	$18.61 million	$29.50 million	View	Listen
5/9/2017	Q1 2017	($2.26)	($2.55)	$3.84 million	$3.10 million	View	Listen
11/3/2016	Q3	($1.92)	($1.98)	$4.39 million	$3.73 million	View	N/A
5/5/2016	Q1	($1.69)	($2.22)	$2.48 million	$0.31 million	View	N/A
2/25/2016	Q4	($1.63)	($1.89)	$3.45 million	$0.23 million	View	Listen
10/29/2015	Q315	($1.52)	($1.66)		$0.09 million	View	Listen
8/6/2015	Q215	($1.14)	($1.51)			View	Listen
4/30/2015	Q115	($1.12)	($1.30)			View	Listen
2/19/2015	Q414	($1.03)	($1.33)			View	Listen
11/5/2014	Q314	($1.04)	($1.01)			View	N/A
7/24/2014	Q214	($0.87)	($1.03)			View	N/A
4/30/2014	Q114	($1.06)	($1.43)			View	N/A
2/19/2014	Q413	($0.78)	($0.72)			View	N/A
11/7/2013	Q313	($0.69)	($0.88)			View	N/A
7/25/2013	Q2 2013	($0.63)	($0.67)			View	N/A
4/25/2013	Q1 2013	($0.62)	($0.66)			View	N/A
2/14/2013	Q4 2012	($0.65)	($15.41)			View	N/A
10/25/2012		($0.55)	($0.52)			View	N/A
7/26/2012		($0.55)	($4.11)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for TESARO (NASDAQ:TSRO)

2017 EPS Consensus Estimate: ($8.64)
2018 EPS Consensus Estimate: ($4.36)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	5	($2.39)	($1.98)	($2.20)
Q2 2017	6	($3.10)	($2.15)	($2.59)
Q3 2017	6	($2.57)	($0.52)	($1.50)
Q4 2017	6	($2.54)	($1.86)	($2.35)
Q1 2018	2	($1.56)	($1.32)	($1.44)
Q2 2018	2	($1.26)	($0.93)	($1.10)
Q3 2018	2	($0.97)	($0.92)	($0.95)
Q4 2018	2	($1.18)	($0.57)	($0.88)

(Data provided by Zacks Investment Research)

Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for TESARO (NASDAQ:TSRO)

Insider Ownership Percentage: 40.50%

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Insider Trades by Quarter for TESARO (NASDAQ:TSRO)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/22/2017	Martin H Jr. Huber	SVP	Sell	592	$118.60	$70,211.20
9/18/2017	James O Armitage	Director	Sell	10,000	$117.13	$1,171,300.00
9/6/2017	Edward C English	VP	Sell	10,862	$134.92	$1,465,501.04
9/5/2017	Orlando Oliveira	SVP	Sell	71	$132.66	$9,418.86
9/1/2017	Grant C. Bogle	VP	Sell	14,167	$135.00	$1,912,545.00
6/6/2017	Edward C English	VP	Sell	8,500	$138.65	$1,178,525.00
4/3/2017	Martin H Jr. Huber	SVP	Sell	829	$153.02	$126,853.58
3/6/2017	Edward C English	VP	Sell	10,000	$178.06	$1,780,600.00
3/2/2017	Edward C English	VP	Sell	229	$177.61	$40,672.69
3/2/2017	Grant C. Bogle	SVP	Sell	1,447	$177.61	$257,001.67
3/2/2017	Mary Lynne Hedley	COO	Sell	3,927	$177.61	$697,474.47
1/3/2017	Martin H. Jr. Huber	SVP	Sell	190	$136.26	$25,889.40
11/2/2016	Martin H Jr. Huber	SVP	Sell	327	$121.29	$39,661.83
9/22/2016	Martin H Jr. Huber	SVP	Sell	408	$108.12	$44,112.96
9/8/2016	Edward C English	VP	Sell	7,000	$88.54	$619,780.00
8/30/2016	Jeffrey H Hanke	VP	Sell	29,166	$86.04	$2,509,442.64
6/30/2016	Jeffrey H Hanke	VP	Sell	12,500	$74.35	$929,375.00
6/10/2016	Edward C English	VP	Sell	7,000	$40.75	$285,250.00
3/18/2016	Arnold L Oronsky	Director	Buy	142,085	$35.19	$4,999,971.15
3/18/2016	Enterprise Associates 13 L New	Major Shareholder	Buy	710,429	$35.19	$24,999,996.51
3/10/2016	Edward C English	VP	Sell	7,000	$43.71	$305,970.00
12/10/2015	Edward C. English	VP	Sell	17,000	$50.19	$853,230.00
9/8/2015	James O Armitage	Director	Buy	500	$54.63	$27,315.00
12/12/2014	James O Armitage	Director	Buy	1,000	$38.16	$38,160.00
9/29/2014	Lawrence M Alleva	Director	Buy	1,100	$26.17	$28,787.00
7/31/2013	Lawrence M Alleva	Director	Buy	1,449	$34.33	$49,744.17
6/5/2013	Peter J Barris	Major Shareholder	Sell	3,583	$39.00	$139,737.00
4/30/2013	Lawrence M Alleva	Director	Buy	1,050	$28.10	$29,505.00
11/1/2012	Lawrence M Alleva	Director	Buy	3,240	$15.45	$50,058.00
8/30/2012	Leon O Moulder Jr	CEO	Buy	10,000	$11.69	$116,900.00

(Data available from 1/1/2013 forward)

Headline Trends for TESARO (NASDAQ:TSRO) Latest Headlines for TESARO (NASDAQ:TSRO)

Source:

Date	Headline
	Zacks: Analysts Anticipate TESARO, Inc. (TSRO) to Announce -$1.09 EPS www.americanbankingnews.com - October 20 at 4:24 PM
	The Foundation for Women's Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to ... - GlobeNewswire (press release) globenewswire.com - October 20 at 9:27 AM
	TESARO, Inc. (TSRO) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - October 19 at 8:46 PM
	AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review finance.yahoo.com - October 19 at 10:07 AM
	TESARO, Inc. (TSRO) Receives New Coverage from Analysts at HC Wainwright www.americanbankingnews.com - October 15 at 7:56 AM
	TESARO, Inc. (TSRO) Short Interest Update www.americanbankingnews.com - October 13 at 1:58 AM
	The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO finance.yahoo.com - October 6 at 11:51 AM
	Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock? finance.yahoo.com - October 6 at 11:51 AM
	First Week of TSRO November 17th Options Trading www.nasdaq.com - October 3 at 1:56 PM
	$118.02 Million in Sales Expected for TESARO Inc (TSRO) This Quarter www.americanbankingnews.com - October 3 at 1:36 AM
	TESARO, Inc. (TSRO) Receives Neutral Rating from Robert W. Baird www.americanbankingnews.com - October 2 at 3:50 PM
	-$1.19 EPS Expected for TESARO, Inc. (TSRO) This Quarter www.americanbankingnews.com - October 1 at 10:26 PM
	Analyzing TESARO (TSRO) and Ultragenyx Pharmaceutical (RARE) www.americanbankingnews.com - October 1 at 2:20 PM
	TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast ... - GlobeNewswire (press release) globenewswire.com - September 30 at 7:49 PM
	TESARO, Inc. (TSRO) SVP Sells $70,211.20 in Stock www.americanbankingnews.com - September 25 at 7:36 PM
	TESARO, Inc. (TSRO) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - September 24 at 8:34 PM
	James O. Armitage Sells 10,000 Shares of TESARO, Inc. (TSRO) Stock www.americanbankingnews.com - September 20 at 7:56 PM
	TESARO Receives Positive CHMP Opinion for ZEJULA® - GlobeNewswire (press release) globenewswire.com - September 16 at 9:53 AM
	$118.02 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter www.americanbankingnews.com - September 15 at 11:00 AM
	TESARO, Inc. (TSRO) Now Covered by Analysts at Royal Bank Of Canada www.americanbankingnews.com - September 14 at 6:06 PM
	Brokerages Expect TESARO, Inc. (TSRO) to Post -$1.19 EPS www.americanbankingnews.com - September 13 at 4:26 AM
	TESARO, Inc. (TSRO) Rating Reiterated by Wedbush www.americanbankingnews.com - September 11 at 5:46 PM
	Citigroup Inc. Reaffirms "Buy" Rating for TESARO, Inc. (TSRO) www.americanbankingnews.com - September 11 at 3:50 PM
	Oppenheimer Holdings, Inc. Reaffirms "Buy" Rating for TESARO, Inc. (TSRO) www.americanbankingnews.com - September 11 at 3:12 PM
	Tesaro Sheds $20 Over The Last Three Days www.benzinga.com - September 8 at 8:35 PM
	TESARO, Inc. (TSRO) Receives "Buy" Rating from Cann www.americanbankingnews.com - September 8 at 1:16 PM
	Grant C. Bogle Sells 14,167 Shares of TESARO, Inc. (TSRO) Stock www.americanbankingnews.com - September 6 at 10:28 PM
	Insider Selling: TESARO, Inc. (TSRO) VP Sells 10,862 Shares of Stock www.americanbankingnews.com - September 6 at 10:26 PM
	TESARO, Inc. (TSRO) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - August 30 at 8:36 PM
	TESARO, Inc. (TSRO) Expected to Post Quarterly Sales of $118.02 Million www.americanbankingnews.com - August 27 at 3:56 AM
	Brokerages Expect TESARO, Inc. (TSRO) Will Announce Earnings of -$1.19 Per Share www.americanbankingnews.com - August 25 at 4:28 PM
	TESARO? Announces Participation at Four Investor Conferences www.nasdaq.com - August 24 at 3:57 PM
	TESARO, Inc. :TSRO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 finance.yahoo.com - August 24 at 3:57 PM
	TESARO, Inc. (TSRO) Receives "Buy" Rating from SunTrust Banks, Inc. www.americanbankingnews.com - August 20 at 9:42 AM
	TESARO, Inc. (TSRO) Receives "Outperform" Rating from Wells Fargo & Company www.americanbankingnews.com - August 20 at 9:42 AM
	Tesaro: Losing Its Edge? - Barron's www.barrons.com - August 19 at 8:27 AM
	Jefferies Group LLC Reiterates $124.00 Price Target for TESARO, Inc. (TSRO) www.americanbankingnews.com - August 18 at 11:22 AM
	TESARO, Inc. (TSRO) Given a $190.00 Price Target by Credit Suisse Group Analysts www.americanbankingnews.com - August 18 at 8:12 AM
	TESARO, Inc. (TSRO) Research Coverage Started at Evercore ISI www.americanbankingnews.com - August 16 at 6:58 PM
	See what the IHS Markit Score report has to say about TESARO Inc. finance.yahoo.com - August 15 at 1:36 AM
	Research Analysts Offer Predictions for TESARO, Inc.'s Q3 2017 Earnings (NASDAQ:TSRO) www.americanbankingnews.com - August 11 at 11:40 AM
	TESARO, Inc. (NASDAQ:TSRO) Expected to Post Q3 2017 Earnings of ($0.66) Per Share www.americanbankingnews.com - August 11 at 11:40 AM
	TESARO, Inc. Expected to Post Q3 2017 Earnings of ($0.56) Per Share (NASDAQ:TSRO) www.americanbankingnews.com - August 11 at 11:40 AM
	Gabelli Brokers Lower Earnings Estimates for TESARO, Inc. (TSRO) www.americanbankingnews.com - August 11 at 10:14 AM
	Q3 2017 EPS Estimates for TESARO, Inc. Cut by Analyst (TSRO) www.americanbankingnews.com - August 11 at 7:48 AM
	Q3 2017 EPS Estimates for TESARO, Inc. (TSRO) Boosted by Wedbush www.americanbankingnews.com - August 11 at 7:48 AM
	TESARO, Inc. (NASDAQ:TSRO) to Post FY2020 Earnings of $6.84 Per Share, SunTrust Banks Forecasts www.americanbankingnews.com - August 10 at 1:50 PM
	Oppenheimer Holdings Analysts Lift Earnings Estimates for TESARO, Inc. (NASDAQ:TSRO) www.americanbankingnews.com - August 10 at 1:32 PM
	TESARO's (NASDAQ:TSRO) Neutral Rating Reiterated at Robert W. Baird www.americanbankingnews.com - August 10 at 12:46 PM
	TESARO, Inc. (NASDAQ:TSRO) Announces Quarterly Earnings Results, Misses Estimates By $0.30 EPS www.americanbankingnews.com - August 9 at 3:48 PM